Using a pharmacogenomic algorithm to guide the treatment of depression.

D. K. Hall-Flavin, J. G. Winner, J. D. Allen, J. J. Jordan, R. S. Nesheim, K. A. Snyder, M. S. Drews, L. L. Eisterhold, Joanna M Biernacka, D. A. Mrazek

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

The objective of this study was to evaluate the potential benefit of utilizing a pharmacogenomic testing report to guide the selection and dosing of psychotropic medications in an outpatient psychiatric practice. The non-randomized, open label, prospective cohort study was conducted from September 2009 to July 2010. In the first cohort, depressed patients were treated without the benefit of pharmacogenomic testing (the unguided group). A DNA sample was obtained from patients in the unguided group, but the results were not shared with either the physicians or patients until the end of the 8-week study period. In the second cohort (the guided group), testing results were provided at the beginning of the 8-week treatment period. Depression ratings were collected at baseline and after 2 weeks, 4 weeks and 8 weeks of treatment using the Quick Inventory of Depressive Symptomatology, Clinician Rated (QIDS-C16) and the 17-item Hamilton Rating Scale for Depression (HAM-D17). Clinician and patient satisfaction was also assessed. The reduction in depressive symptoms achieved within the guided treatment group was greater than the reduction of depressive symptoms in the unguided treatment group using either the QIDS-C16 (P=0.002) or HAM-D17 (P=0.04). We concluded that a rapidly available pharmacogenomic interpretive report provided clinical guidance that was associated with improved clinical outcomes for depressed patients treated in an outpatient psychiatric clinic setting.

Original languageEnglish (US)
JournalTranslational Psychiatry
Volume2
StatePublished - 2012

Fingerprint

Pharmacogenetics
Depression
Psychiatry
Therapeutics
Ambulatory Care Facilities
Patient Satisfaction
Cohort Studies
Outpatients
Prospective Studies
Physicians
Equipment and Supplies
DNA
Pharmacogenomic Testing

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Cellular and Molecular Neuroscience

Cite this

Hall-Flavin, D. K., Winner, J. G., Allen, J. D., Jordan, J. J., Nesheim, R. S., Snyder, K. A., ... Mrazek, D. A. (2012). Using a pharmacogenomic algorithm to guide the treatment of depression. Translational Psychiatry, 2.

Using a pharmacogenomic algorithm to guide the treatment of depression. / Hall-Flavin, D. K.; Winner, J. G.; Allen, J. D.; Jordan, J. J.; Nesheim, R. S.; Snyder, K. A.; Drews, M. S.; Eisterhold, L. L.; Biernacka, Joanna M; Mrazek, D. A.

In: Translational Psychiatry, Vol. 2, 2012.

Research output: Contribution to journalArticle

Hall-Flavin, DK, Winner, JG, Allen, JD, Jordan, JJ, Nesheim, RS, Snyder, KA, Drews, MS, Eisterhold, LL, Biernacka, JM & Mrazek, DA 2012, 'Using a pharmacogenomic algorithm to guide the treatment of depression.', Translational Psychiatry, vol. 2.
Hall-Flavin DK, Winner JG, Allen JD, Jordan JJ, Nesheim RS, Snyder KA et al. Using a pharmacogenomic algorithm to guide the treatment of depression. Translational Psychiatry. 2012;2.
Hall-Flavin, D. K. ; Winner, J. G. ; Allen, J. D. ; Jordan, J. J. ; Nesheim, R. S. ; Snyder, K. A. ; Drews, M. S. ; Eisterhold, L. L. ; Biernacka, Joanna M ; Mrazek, D. A. / Using a pharmacogenomic algorithm to guide the treatment of depression. In: Translational Psychiatry. 2012 ; Vol. 2.
@article{b4406dce422147208643bc6fb07858bd,
title = "Using a pharmacogenomic algorithm to guide the treatment of depression.",
abstract = "The objective of this study was to evaluate the potential benefit of utilizing a pharmacogenomic testing report to guide the selection and dosing of psychotropic medications in an outpatient psychiatric practice. The non-randomized, open label, prospective cohort study was conducted from September 2009 to July 2010. In the first cohort, depressed patients were treated without the benefit of pharmacogenomic testing (the unguided group). A DNA sample was obtained from patients in the unguided group, but the results were not shared with either the physicians or patients until the end of the 8-week study period. In the second cohort (the guided group), testing results were provided at the beginning of the 8-week treatment period. Depression ratings were collected at baseline and after 2 weeks, 4 weeks and 8 weeks of treatment using the Quick Inventory of Depressive Symptomatology, Clinician Rated (QIDS-C16) and the 17-item Hamilton Rating Scale for Depression (HAM-D17). Clinician and patient satisfaction was also assessed. The reduction in depressive symptoms achieved within the guided treatment group was greater than the reduction of depressive symptoms in the unguided treatment group using either the QIDS-C16 (P=0.002) or HAM-D17 (P=0.04). We concluded that a rapidly available pharmacogenomic interpretive report provided clinical guidance that was associated with improved clinical outcomes for depressed patients treated in an outpatient psychiatric clinic setting.",
author = "Hall-Flavin, {D. K.} and Winner, {J. G.} and Allen, {J. D.} and Jordan, {J. J.} and Nesheim, {R. S.} and Snyder, {K. A.} and Drews, {M. S.} and Eisterhold, {L. L.} and Biernacka, {Joanna M} and Mrazek, {D. A.}",
year = "2012",
language = "English (US)",
volume = "2",
journal = "Translational Psychiatry",
issn = "2158-3188",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Using a pharmacogenomic algorithm to guide the treatment of depression.

AU - Hall-Flavin, D. K.

AU - Winner, J. G.

AU - Allen, J. D.

AU - Jordan, J. J.

AU - Nesheim, R. S.

AU - Snyder, K. A.

AU - Drews, M. S.

AU - Eisterhold, L. L.

AU - Biernacka, Joanna M

AU - Mrazek, D. A.

PY - 2012

Y1 - 2012

N2 - The objective of this study was to evaluate the potential benefit of utilizing a pharmacogenomic testing report to guide the selection and dosing of psychotropic medications in an outpatient psychiatric practice. The non-randomized, open label, prospective cohort study was conducted from September 2009 to July 2010. In the first cohort, depressed patients were treated without the benefit of pharmacogenomic testing (the unguided group). A DNA sample was obtained from patients in the unguided group, but the results were not shared with either the physicians or patients until the end of the 8-week study period. In the second cohort (the guided group), testing results were provided at the beginning of the 8-week treatment period. Depression ratings were collected at baseline and after 2 weeks, 4 weeks and 8 weeks of treatment using the Quick Inventory of Depressive Symptomatology, Clinician Rated (QIDS-C16) and the 17-item Hamilton Rating Scale for Depression (HAM-D17). Clinician and patient satisfaction was also assessed. The reduction in depressive symptoms achieved within the guided treatment group was greater than the reduction of depressive symptoms in the unguided treatment group using either the QIDS-C16 (P=0.002) or HAM-D17 (P=0.04). We concluded that a rapidly available pharmacogenomic interpretive report provided clinical guidance that was associated with improved clinical outcomes for depressed patients treated in an outpatient psychiatric clinic setting.

AB - The objective of this study was to evaluate the potential benefit of utilizing a pharmacogenomic testing report to guide the selection and dosing of psychotropic medications in an outpatient psychiatric practice. The non-randomized, open label, prospective cohort study was conducted from September 2009 to July 2010. In the first cohort, depressed patients were treated without the benefit of pharmacogenomic testing (the unguided group). A DNA sample was obtained from patients in the unguided group, but the results were not shared with either the physicians or patients until the end of the 8-week study period. In the second cohort (the guided group), testing results were provided at the beginning of the 8-week treatment period. Depression ratings were collected at baseline and after 2 weeks, 4 weeks and 8 weeks of treatment using the Quick Inventory of Depressive Symptomatology, Clinician Rated (QIDS-C16) and the 17-item Hamilton Rating Scale for Depression (HAM-D17). Clinician and patient satisfaction was also assessed. The reduction in depressive symptoms achieved within the guided treatment group was greater than the reduction of depressive symptoms in the unguided treatment group using either the QIDS-C16 (P=0.002) or HAM-D17 (P=0.04). We concluded that a rapidly available pharmacogenomic interpretive report provided clinical guidance that was associated with improved clinical outcomes for depressed patients treated in an outpatient psychiatric clinic setting.

UR - http://www.scopus.com/inward/record.url?scp=84873966738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873966738&partnerID=8YFLogxK

M3 - Article

C2 - 23047243

AN - SCOPUS:84873966738

VL - 2

JO - Translational Psychiatry

JF - Translational Psychiatry

SN - 2158-3188

ER -